查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1544663

自体免疫性溶血性贫血治疗市场、机会、成长动力、产业趋势分析与预测，2024-2032

Autoimmune Hemolytic Anemia Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 250 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球自体免疫溶血性贫血 (AIHA) 治疗市场预计 2024 年至 2032 年复合年增长率为 6%。自体免疫性溶血性贫血是一种免疫系统错误地攻击红血球的疾病，由于人们所认识的提高和诊断能力的提高，它越来越受到人们的认识。该领域研究数量的激增将为市场提供支持。

2024年5月，法国的一项回顾性研究显示，三分之一患有严重自体免疫性溶血性贫血（AIHA）（包括冷凝集素病）的成年人在一週后对静脉注射免疫球蛋白（ IVIG）作为辅助治疗产生正面反应。值得注意的是，超过一半 (57%) 的可取得血液资料的患者在 IVIG 给药两週后表现出治疗反应。

此外，该领域正在进行的研究和开发正在推出新的治疗方法，这些治疗方法具有增强的功效和最小化的副作用，从而推动了市场的成长。先进治疗方法的激增，加上自体免疫疾病发生率的上升，极大地促进了 AIHA 治疗市场的扩张。

AIHA 治疗市场根据疾病类型、治疗类型、给药途径、配销通路和地区进行分类。

按疾病类型、治疗类型和地区细分，AIHA 治疗市场预计寒冷性自体免疫溶血性贫血细分市场将显着成长。冷 AIHA 是由于低温诱导产生针对红血球的冷凝集素而引起的，它带来了独特的治疗挑战。然而，针对感冒 AIHA 的标靶治疗和创新方法的进步有望推动这一领域的成长。改进的诊断工具和客製化的治疗计划正在扩大这些疗法的采用，促进市场的整体扩张。

免疫抑制剂领域有望占据 AIHA 治疗市场的很大一部分。这些药物包括皮质类固醇和尖端生物疗法，透过抑制免疫系统对红血球的误导性攻击，在治疗自体免疫疾病方面发挥关键作用。它们不仅可以缓解 AIHA 患者的症状，还可以防止病情復发。随着先进免疫抑制药物供应的激增以及对更有效治疗方法的不断研究，对这些疗法的需求正在上升。此外，免疫抑制方案的创新有望提高患者的治疗效果并刺激市场成长。

2024 年至 2032 年间，欧洲将在 AIHA 治疗市场扩张中发挥关键作用。该地区强大的医疗基础设施在大量医学研究投资的支持下，为先进 AIHA 疗法的开发和采用铺平了道路。欧洲国家以其严格的监管框架确保新兴疗法的安全性和有效性，为市场成长创造了有利的环境。再加上欧洲自体免疫疾病的高盛行率以及领先製药公司倡导创新研究的存在，这些因素共同推动了该地区 AIHA 治疗市场的发展。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 全球自体免疫疾病及相关疾病的盛行率不断上升
      • 生物技术和免疫学的进展
      • 医疗保健专业人员和患者的意识不断提高
    • 产业陷阱与挑战
      • 与新疗法和持续治疗方案相关的高成本
      • 新治疗方式的监管挑战和严格的审批流程
  • 成长潜力分析
  • 管道分析
  • 未来市场趋势
  • 监管环境
  • 专利分析
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按疾病类型，2021 - 2032

  • 主要趋势
  • 温性自体免疫溶血性贫血
  • 寒冷性自体免疫溶血性贫血

第 6 章：市场估计与预测：按治疗类型，2021 - 2032 年

  • 主要趋势
  • 皮质类固醇
  • 免疫抑制剂
  • 其他治疗类型

第 7 章：市场估计与预测：按管理途径，2021 - 2032 年

  • 主要趋势
  • 可注射
  • 口服
  • 其他给药途径

第 8 章：市场估计与预测：按配销通路划分，2021 - 2032 年

  • 主要趋势
  • 医院药房
  • 零售药房
  • 电子商务
  • 其他分销管道

第 9 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 10 章：公司简介

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Baxter International Inc.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • Johnson and Johnson Services, Inc.
  • Merck and Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Sanofi
  • Takeda Pharmaceutical Company Limited
简介目录
Product Code: 10198

Global Autoimmune Hemolytic Anemia (AIHA) Treatment Market is expected to register a 6% CAGR from 2024 to 2032. This expansion is largely attributed to advancements in treatment options and a growing prevalence of the disease. Autoimmune hemolytic anemia, a condition where the immune system mistakenly attacks red blood cells, is becoming increasingly recognized due to heightened awareness and improved diagnostic capabilities. The boom in number of studies across the field will support the market.

In May 2024, a retrospective study from France revealed that one-third of adults with severe autoimmune hemolytic anemia (AIHA), including cold agglutinin disease, responded positively to intravenous immunoglobulins (IVIG) as an adjunct therapy after a week. Notably, over half (57%) of the patients with accessible blood data exhibited a treatment response two weeks post-IVIG administration.

Moreover, ongoing research and development in the field are introducing new treatments that boast enhanced efficacy and minimized side effects, fueling the market's growth. The surge in advanced therapy availability, coupled with the rising incidence of autoimmune disorders, significantly bolsters the AIHA treatment market's expansion.

The AIHA treatment market is categorized based on disease type, treatment type, route of administration, distribution channel, and region.

Segmented by disease type, treatment type, and region, the AIHA treatment market anticipates notable growth in the cold autoimmune hemolytic anemia segment. Cold AIHA, which arises from cold temperatures inducing the production of cold agglutinins that target red blood cells, poses distinct treatment challenges. However, advancements in targeted therapies and innovative approaches specifically for cold AIHA are poised to propel growth in this segment. Improved diagnostic tools and customized treatment plans are amplifying the adoption of these therapies, bolstering the market's overall expansion.

The immunosuppressive agents segment is on track to secure a substantial portion of the AIHA treatment market. These agents, encompassing corticosteroids and cutting-edge biological therapies, are pivotal in managing autoimmune disorders by curbing the immune system's misguided attacks on red blood cells. They not only alleviate symptoms but also stave off relapses in AIHA patients. With a surge in advanced immunosuppressive drug availability and continuous research into more potent treatments, the demand for these therapies is on the rise. Furthermore, innovations in immunosuppressive options promise to elevate patient outcomes and stimulate market growth.

Between 2024 and 2032, Europe is set to play a pivotal role in the AIHA treatment market expansion. The region's robust healthcare infrastructure, bolstered by substantial medical research investments, paves the way for the development and uptake of advanced AIHA treatments. European nations, with their stringent regulatory frameworks, ensure the safety and efficacy of emerging therapies, creating a favorable landscape for market growth. Coupled with Europe's high autoimmune disorder prevalence and the presence of leading pharmaceutical firms championing innovative research, these factors collectively propel the AIHA treatment market in the region.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of autoimmune disorders and associated conditions, globally
      • 3.2.1.2 Advances in biotechnology and immunology
      • 3.2.1.3 Rising awareness among healthcare professionals and patients
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High costs associated with novel therapies and ongoing treatment regimens
      • 3.2.2.2 Regulatory challenges and stringent approval processes for new treatment modalities
  • 3.3 Growth potential analysis
  • 3.4 Pipeline analysis
  • 3.5 Future market trends
  • 3.6 Regulatory landscape
  • 3.7 Patent analysis
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Warm autoimmune hemolytic anemia
  • 5.3 Cold autoimmune hemolytic anemia

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Corticosteroids
  • 6.3 Immunosuppressive agents
  • 6.4 Other treatment types

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Injectable
  • 7.3 Oral
  • 7.4 Other routes of administration

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacy
  • 8.3 Retail pharmacy
  • 8.4 E-commerce
  • 8.5 Other distribution channels

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 AbbVie Inc.
  • 10.2 Amgen Inc.
  • 10.3 AstraZeneca
  • 10.4 Biogen Inc.
  • 10.5 Bristol-Myers Squibb Company
  • 10.6 Baxter International Inc.
  • 10.7 Eli Lilly and Company
  • 10.8 Gilead Sciences, Inc.
  • 10.9 Johnson and Johnson Services, Inc.
  • 10.10 Merck and Co., Inc.
  • 10.11 Novartis AG
  • 10.12 Pfizer Inc.
  • 10.13 F. Hoffmann-La Roche Ltd
  • 10.14 Sanofi
  • 10.15 Takeda Pharmaceutical Company Limited